---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055442"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:47:37.891894+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Imara reports Q3 net loss $13.6M; tovinontrine Phase 2b interim data expected Q4 2021

## Summary
- Net loss $13.6M ($0.55/share) vs $12.4M ($0.72/share) in Q3 2020; cash & investments $102.8M.
- R&D expenses $10.4M; FY2021 R&D guidance $40-45M, G&A $12-13M; cash runway into Q1 2023.
- Phase 2b Ardent (SCD) and Forte (beta-thalassemia) trials fully enrolled; interim data Q4 2021, primary analysis Q1 2022.
- New pipeline asset IMR-261 (Nrf2 activator) acquired; preclinical data to be presented at ASH 2021.
- Hired cardiologist Dr. Toni Bransford to lead HFpEF Phase 2 trial of tovinontrine; trial expected to start 2022.

## SEC filing metadata
- accession: 0001564590-21-055442
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/0001564590-21-055442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/imra-8k_20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055442
- JSON: https://secwatch.observer/filing/0001564590-21-055442.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.